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Abstract 
Drug targets in the central nervous system are numerous and important for drug therapy e.g. 
of pain, psychiatric disorders or epilepsy. Drugs and other xenobiotics as well as nutrients 
cannot freely cross the blood brain barrier or freely enter cells across plasma membranes and 
therefore require transport systems. This overview summarizes the current knowledge on the 
expression of drug transporters in barriers shielding the central nervous system form the 
systemic circulation and as such controlling the pharmacokinetics of drugs in the central 
nervous system. The main drug transporter families covered are SLCO, SCL22A, ABCB and 
ABCC, as genes of these families code for numerous drug transporters. While knowledge on 
mRNA expression in humans, rats and mice is remarkable, there is clearly a gap in knowledge 
on the subcellular expression of transporters in specific cells in the central nervous system and 
in the barriers shielding the central nervous system from the systemic circulation. Recent 
methodological developments including synthesis of drugs and endogenous substances as 
markers for imaging will in the future allow investigating the function and physiologic role of 
transporters in the central nervous systems including difficult to address systems like the 
choroid plexus in vivo. 
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Introduction 
All organs in the mammalian body are connected via the blood circulatory system, which 
provides both the supply of vital nutrients and disposes waste products. In most instances, 
drugs also reach their target via the circulatory system regardless of the route of application. 
Organs are separated from the circulatory system by barriers, which may be leaky like e.g. in 
the liver or very tight like in the brain. The brain is separated from the blood by the blood-
brain barrier (BBB) and from the cerebrospinal fluid (CSF) by the choroid plexus (CP) [1, 2]. 
In addition, the brain also communicates with body extracellular fluids via the arachnoid 
epithelium [3], but this pathway contributes only minor to the exchange and is not subject of 
this overview. In order to cross barriers, which ultimately are always plasma membranes, 
transport systems are needed [4, 5]. Moreover, a tissue specific expression of transporters 
allows the body to accumulate substances, like e.g. drugs in an organ-specific manner [1, 4]. 
The tightness of the BBB severely limits the access of drugs to the brain and presents major 
challenge in the development of drugs with targets in the central nervous system (CNS) [6-8]. 
Therefore, the aim of this review is to summarize the current knowledge on the expression of 
drug transporters in the BBB and in the CP. As the retina is also part of the CNS, transporters 
in the blood-retina barrier (BRB) will also be addressed. Furthermore, we will also highlight 
the role of the transporters encountered by drugs and other substances once they have crossed 
the barriers surrounding the tissues of the CNS. 
 
Drug Transporters 
Solutes, like drugs need transporters to enter or exit cells. Generally, transporters mediating 
the cellular uptake of drugs belong to the superfamily of solute carriers (SLC). Efflux of drugs 
(or their metabolites) frequently occurs against a concentration gradient and is often mediated 
by members of the ATP-binding cassette (ABC) transporters. Numerous reviews have been 
published on both superfamilies of transporters. The SLC superfamily represents currently 52 
families and 395 genes for individual transporters and has been covered recently in a special 
issue [9]. Human ABC transporter genes number to 48 members and are divided into seven 
families [10], but not all of them act as transporters [11]. It is beyond the scope and space of 
this review to describe the individual drug transporter families. This overview will focus on 
members of the SLCO and SLC22A gene families, which are well known to mediate in 
addition to endogenous substrates the transport of drugs. Among the ABC protein families, 
multidrug resistance protein 1 (MDR1) (ABCB1), ABCG2 (also called BCRP, ABCG2) and 
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members of the ABCC family are known to be important drug and drug metabolite 
transporters and will therefore be covered here. 
 
Human drug transporters being members of the SLC superfamily and expressed in cerebral 
blood tissue barriers are listed together with rodent transporters in tables 1 to 5. Rodent 
species are included as they are used as preclinical species in drug development and as they 
allow in vivo experiments not possible in humans for investigating their role in drug transport 
in the CNS. In these tables a selection of references (we apologize for omissions) had to be 
made and data on transport systems obtained from microperfusion experiments as well as 
from work with microcapillary endothelial cell lines are not included. Microperfusion 
experiments are most valuable for the elucidation of the in vivo situation for drug access to 
brain tissue but face the difficulty that many drug transporters have an overlapping substrate 
specificity [12-14]. Brain capillary endothelial cell lines and very likely also other established 
cell lines display altered transporter expression levels in comparison to their in vivo 
counterparts [15, 16]. It should be realized that there are often conflicting data in the 
literature. Good examples are the members of the ABCC family, about which conflicting data 
on the expression in the BBB exist up to date [17]. This may relate to the fact that for animals, 
within a species, different strains show different transporter expression. E.g. in mice, mouse 
multidrug resistance-associated protein 2 (MRP2) could be detected in the BBB of C57BL/6, 
Swiss and SvJ, but not FVB mice, while liver and kidney showed positive staining in all 
strains [18]. Similarly, the expression levels of the mouse monocarboxylate transporter MCT1 
in the BBB of C57BL/6J mice were significantly lower than in ddY or FVB mice, while the 
expression of mBCRP was significantly higher in C57BL/6J mice compared to ddY or FVB 
mice when analyzed by quantitative targeted proteomics [19]. In human studies, tissue 
procurement and storage prior to analysis as well as sampling biases will considerably 
contribute to variable data sets. For protein expression, preference to data obtained from 
proteomic approaches where available was given over data obtained by Western blotting. 
Transporter expression in blood neural tissue barriers has additionally been covered in many 
overviews [17, 20-31]. 
 
Blood-Brain-Barrier 
In order to provide a stable environment for the CNS, the BBB needs to be able to tightly 
control the access of substances to the brain. To this end, the endothelial cells lining the walls 
of the brain capillaries form together with tight junctions an impervious barrier [2]. Brain 
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access of substances (e.g. nutrients like e.g. D-glucose) is consequently controlled by 
transport proteins specifically expressed in the luminal and/or abluminal membrane of brain 
capillary endothelial cells [2]. Nutrients are transported into the brain by influx systems such 
as for example amino acids by members of the SLC1A family [32]. Many of these transporters 
are equilibrative, i.e. they cannot work against concentration gradients. Extrusion of 
substances from brain occurs at the luminal membrane and is mediated by ABC transporters 
like MDR1 [33]. ABC transporters utilize energy provided from ATP hydrolysis and can 
therefore establish steep concentration gradients. While SLC transporters expressed in plasma 
membranes are often uptake transporters, some members act as exchanger of solutes and 
consequently mediate may mediate efflux of a substrate in exchange for uptake of another 
substance [9]. Consequently, the direction of solute transport by such transporters has to be 
determined experimentally, ideally in situ in the organ of interest. 
 
Drug transporters being members of the SLC superfamily and expressed in BBB are listed in 
table 1. Specifically, the protein expression of several SLC superfamily members involved in 
drug transport (4 organic anion transporting polypeptides (OATPs) (SLCO), two organic 
cation transporters (OCTs) (SLC22A), one organic cation transporter novel type (OCTN) 
(SLC22A), one concentrative nucleoside transporter (CNT) (SLC28A) and two equilibrative 
nucleoside transporters (ENTs) (SLC29A)) has been reported for human BBB (Table 1). SLC 
family members are either facilitating uptake transporters secondary active transporters 
capable of working against concentration gradients [9]. Consequently, drug transporters 
expressed in the luminal membrane of the BBB are potential entry sites for drugs or toxins 
into the BBB. In the case of non-polar expression (i.e. in the luminal and in the abluminal 
membrane of the BBB, these transporters may allow their substrates to cross the endothelial 
cells of the BBB and the entry into the brain. The number of substrates including drugs for 
SLC family members known today is overwhelming and listing them is beyond the scope of 
this overview. Lists of substrates can be found in the following (as well as many additional) 
reviews: for OATPs [13, 34, 35]; for OATs [36-38]; for OCTs [37, 39]; for CNTs [40, 41]; 
for ENTs [41, 42]and for MATEs [43, 44]. 
 
Several examples demonstrate indirectly and directly the pharmacologic and toxicologic role 
of SLC transporters in the BBB of humans. Drugs used for treatment of pain often need to 
enter the CNS [45]. Triptans are drugs used to treat migraine. It was recently demonstrated 
that several triptans are substrates of OATP1A2 expressed in BBB (table 1) [46]. Hence, it is 
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reasonable that hydrophilic triptans may use OATP1A2 to cross the BBB. The relative 
transport rate of OATP1A2-mediated transport decreases from triptans with tertiary to triptans 
with primary amines in heterologous expression systems [46]. While transport of drugs across 
the BBB is considered to be beneficial this is not the case for toxins. This is exemplified by an 
incidence in Brazil, where 126 patients of a hemodialysis unit suffered from a microcystin 
intoxication and 60 patients subsequently died [47]. The patients developed acute 
neurotoxicity and subacute hepatotoxicity. Expressing OATP1A2 in Xenopus laevis oocytes 
allowed demonstrating that this transporter mediates uptake of microcystin [48]. Moreover, 
OATP1A2 expression was required for microcystin to exert its toxic effects on oocytes. 
Lately, it was reported that OATP1A2 is expressed in neurons in human brain [49]. This 
finding adds an additional piece to the mechanistic understanding of microcystin toxicity: 
Microcystin inhibits protein phosphatases at nanomolar concentrations [50]. Hence the 
expression of OATP1A2 in neurons may allow microcystin, once it has crossed the BBB, the 
entry into neurons followed by impairment of neuronal functions. Looking at an endogenous 
compound, thyroid hormones are instrumental for the development of brain and in adult life 
for metabolic adaptation [51]. OATP1C1, which is expressed at the BBB (table 1) [52] is a 
high-affinity thyroid hormone transporter [53] and consequently allows the entry of thyroid 
hormones into brain. These examples clearly demonstrate that expression of transport proteins 
in the BBB in addition to endogenous substances allows the entry of xenobiotics into the 
brain. Hence, understanding the molecular properties of transporters working in the BBB will 
contribute to a better understanding of the penetration of drugs across the BBB to reach 
pharmacodynamics targets in the brain. Therefore, the relevance of the BBB as a selective 
guard of the brain is not only recognized by physiologists and pharmacologists but has also 
initiated large efforts for developing tools to study the impact of BBB early in drug 
development [8, 54]. 
 
ABC transporters are mostly cellular efflux transporters and either act as cellular defense 
systems for substances or export them from the cytoplasm [9]. They are often located in 
strategic organ boundaries including BBB, where they are most important for controlling 
access to body sanctuaries [55]. The importance of ABC transporters is further emphasized by 
the observation that more than 20 (out of 48) human ABC transporters are important in 
various acquired and inherited human diseases [56]. Drug transporters being members of the 
ABC superfamily and expressed in human BBB are listed in table 2. The protein expression 
of several ABC transporter superfamily members involved in drug transport (one MDR) 
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(ABCB), four MRPs (ABCC), and one ABCG (ABCG) has been reported for human BBB 
(Table 2). With respect to drug transport, members of the ABCB, ABCC and ABCG family are 
capable of transporting numerous drugs. List of substrates including drugs for drug 
transporting ABC family members can be found e.g. in the following reviews: [27, 57-67]. 
 
The brain protective role of ABC transporters at the BBB is best illustrated with the clinical 
studies aimed at inhibiting MDR1 in drug treatment of cancer. For example, in a phase I trial 
coadministration of etoposide and cyclosporine lead to more severe nausea in some patients 
receiving both drugs [68]. In another phase I study where etoposide and the second generation 
MDR1 inhibitor PSC 833 were combined to treat cancer patients, severe ataxia was observed 
as dose-limiting toxicity of PSC833 [69]. In this case, the MDR1 inhibitor allowed etoposide 
to cross the BBB inducing neurotoxicity. The same toxicity was later observed in a phase III 
trial [70]. Similarly, a high-dose oral tamoxifen phase I trial in combination with verapamil 
revealed dose-limiting neurologic side effects [71]. Taken together, these few examples in 
humans demonstrate the importance of luminal ABC-transporters in BBB as gate keepers 
preventing or lowering the exposure of the brain to potentially neurotoxic agents. In principle, 
given access of a substrate into BBB, abluminal ABC-transporters should enhance the 
exposure of the brain to their substrates. To the best of our knowledge we found no such 
examples in the literature. 
 
Choroid Plexus 
The CP is located in the lateral third and forth brain ventricles and produces the cerebrospinal 
fluid. It is a highly vascularized organ containing in the stroma loose connective tissue and a 
fenestrated endothelium. A tight monolayer of CP epithelial cells connected by tight junctions 
near the apical surface forms the blood cerebrospinal fluid barrier (BCSFB) [72-74]. In 
addition to its central role in the production of cerebrospinal fluid (CSF), it also removes 
organic anions as well as drugs and drug metabolites from the CSF, making the CP an 
important detoxifying system for the CSF [72, 73]. 
 
The protein expression of several SLC superfamily members involved in drug transport has so 
far been reported for CP. In humans (two OATPs and two OATs are identified in CP (Table 
3) and one member of the ABCB and two members of the ABCC family have been 
demonstrated at the protein level (table 4). Inferring from rodent tissues, the two MRPs likely 
are expressed in the basolateral membrane of human CP epithelial cells and consequently 
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mediate export of substances form the CSF back into blood after their uptake across the apical 
membrane. The individual role of these transporters in drug transport cannot be directly 
assessed in humans despite the fact that e.g. analgetics and anticancer drugs are administered 
to patients via an intrathecal route. Clearance of such drugs from the CSF is obvious, but in 
addition to the CP, the villi of the arachnoids may also be involved in elimination of 
substances from the CSF. Drug transporter expression in arachnoid villi is still a largely 
uncharted area. In addition, the hydrodynamics of the cerebrospinal fluid, which may 
contribute to drug elimination from this body compartment is rather controversial [74, 75]. 
 
Blood Ocular Barrier 
The retina is an organ rich in neurons. The retina is exposed on the anterior side to the 
vitreous humor and at the posterior side to the choroid. In the retina, there exist two BRB, 
namely the inner BRB formed by retinal capillary endothelial cells and the outer BRB formed 
by the retinal pigmented epithelial cells [21, 76]. These two barriers prevent uncontrolled 
entry of blood constituents into the eye. Consequently, either one or both of these barriers 
needs to be overcome by drugs, which are systemically administered for treatment of retinal 
diseases. 
 
The protein expression of several SLC superfamily members involved in drug transport (three 
OATPs, one OATs and one member of the ABCB and ABCC families each has so far been 
reported for human BRB (Table 5). Direct information on the role of transporters in drug 
permeation through the BRB in humans is missing, but it should be noted that systemically 
administered antibiotics reach the vitreous humor, e.g. ciprofloxacin [77] or daptomycin [78]. 
Ciprofloxacin is known to interact with OATPs [79]. Also, prostaglandins are used as first 
line treatment of glaucoma [80] and are substrates of OATPs [81, 82]. While these examples 
do not prove that transport systems are involved in the ocular disposition of drugs, they are 
nevertheless strongly indicative, as in particular daptomycin is rather membrane impermeable. 
 
Animal models for investigating the role of drug transporters in the central nervous 
system 
Animal models are a potent means to investigate the role of transporters in the CNS. Such 
models yield most valuable information on the function of drug transporters both at blood 
tissue barriers in the CNS as well as on their physiologic role in the CNS. For example, more 
than 50 years ago it was demonstrated in a goat model that phenolsulfonphthalein (also called 
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phenol red), which at physiologic pH is a dianionic compound and the anionic angiographic 
contrast agent diodrast are actively transported out from the CSF into blood [83]. The 
understanding and consequently appreciation of the role of transporters in the BBB changed 
with the seminal work by Schinkel and coworkers who demonstrated that in mice with an 
inactivated Mdr1a gene the issue concentration in brain was 87-fold increased in comparison 
to controls and 22.4 fold for vinblastine [84]. In addition, the same team found no negative 
effect on the physiology of mice when both Mdr1 genes were inactivated, indicating that in 
this species mMDR1 (table 2) plays no vital role [85]. In contrast, mice with a disrupted 
Abcg2 gene gave conflicting results on the role of mABCG2 in the BBB (table 2) [86]. 
However, if studies were performed in mice, which in addition to Abcg2 had also disrupted 
Mdr1 genes, it became clear that for some drugs Abcg2 contributes to preventing drugs from 
crossing the BBB. This example nicely illustrates the complexity of in vivo studies with drugs 
sharing multiple transporters. Also the role of mOATPs (table 1) in penetrating the BBB 
became evident in mice with a knockout of Slco1a4 [87] as well as with the Slco1a/1b locus, 
as in such animals statins showed a considerably lower entry into brain [88]. 
 
Genetically modified mice can also be used to study the efflux of drug metabolites produced 
in brain. Oseltamivir is an ethylester prodrug for Ro 64-0802. The latter is an inhibitor of 
neuraminidase and as such used in the prophylaxis and treatment of influenza virus infections 
[89]. This drug is associated with adverse psychiatric effects [90]. Oseltamivir is activated by 
carboxylesterase 1 [89], which is among other organs also expressed in brain [91]. Studies 
with Abcb1 knockout mice showed that mMDR1 isoforms limit brain access of oseltamivir 
across the BBB [92]. Mircoinjection of RO 64-0802 into the brain of rats deficient either for 
Abcc4 or SLC22a8 demonstrated that both, mMRP4 (table 2) and mOAT3 (table 1) are 
involved in the elimination of RO 64-0802 from the brain across the BBB [93]. 
 
The opposite localization with respect to the lumen of blood vessels in the BBB (table 4) and 
in the CP (table 5) of MDR1 and ABCG2 leads to differential effects on the brain entry of 
drugs across the BBB and into the CSF. Mice with an Abcb1 or Abcg2 knockout show an 
increased accumulation of topotecan in the brain parenchyma, while its penetration into the 
CSF is reduced [94]. In double knockout animals, these effects were additive for both 
barriers. In mice with and inactivated Scl22a8 gene, accumulation of fluorescein into the 
isolated CP was greatly reduced in comparison to wild type animals [95]. Hence, knock-out 
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mice provide a most valuable tool to investigate the impact of transporters not only in the 
BBB but also in CP [96].  
 
OATP1C1 was identified as a high affinity thyroxine transporter [53], which is expressed at 
the BBB (table 1) and in the CP (table 5). Mice having an inactivated Oatp1c1 gene showed a 
significantly reduced brain content of T4 and T3 with no change in the plasma concentration 
of these two thyroid hormones [97], clearly demonstrating the important role of this 
transporter for thyroid hormone supply to the brain. In the same knockout mice strain, uptake 
of sulforhodamine 101 into astrocytes of the hypocampus is severely impaired [98]. 
 
Outlook 
Ample evidence accumulated in recent years indicates the importance of transporters 
expressed in BBB, CP and BRB for mediating the passage of drugs as well as nutrients and 
metabolites. Great progress has also been made, in particular in model animals, in the 
identification and quantification of transport proteins in these barriers. The depth of 
knowledge however varies considerably between the different barriers and the different 
species as the availability of CP and even more so of the BRB is very limited, in particular 
from humans. Hence, alternate tools such as good antibodies are urgently needed for defining 
the transporter inventory in these barriers. Importantly, antibodies have a major advantage in 
that they are key to define the subcellular expression of transporters in barriers. As movement 
of substances across barriers into and out from the CNS is often unidirectional and in some 
instance may occur against concentration gradients, exact knowledge on the subcellular 
expression of transporters together with and understanding in their transport mechanism is 
key for understand the contribution of individual transporters to the passage or blockage of 
compounds across these barriers. Progress in this area may in future come from a systems 
biology approach aimed at generating antibodies against a larger number of human proteins, 
like for example the Human Protein Atlas project [99]. In addition, advances in the field of 
targeted proteomics should certainly help to increase the knowledge needed for developing 
pharmacokinetic models for the uptake of drugs into the brain and for the export of drug 
metabolites from the brain [16]. In addition, for developing novel kinetic models for brain 
uptake and export, the contribution of drug metabolism, e.g. in BBB has to be taken into 
account [23]. 
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Imaging methods and in particular positron emission tomography (PET) have made rapid and 
large progress in recent years such that PET becomes a feasible tool for studying the function 
of transporters in vivo [100]. First studies with healthy subjects [101] and with patients 
suffering from epilepsy [102, 103] have clearly provided data demonstrating that imaging of 
in vivo function of transporters not only in animal models but also in humans will soon 
become a very valuable tool for understanding drug transport across barriers shielding the 
brain. It is important to note that transporter function in vivo cannot only be monitored by 
PET, but also by single-photon emission-coupled tomography [104]. The development of 
novel imaging probes should in the future certainly help the development of novel drugs with 
targets in the CNS, as their passage through the barriers can be followed in vivo. This 
methodology, together with stringent quality control of the label [105], will certainly also help 
to address issues of transporter based drug-drug interactions at the BBB, where clearly more 
information for clinics is needed [20, 106, 107]. 
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Table 1 Expression of SLC transporters at the blood brain barrier 
 
transporter mRNA expression protein expression cellular localization 
human    
OATP1A2 
 
brain [108, 109] brain [110] brain capillary endothelial 
cells [110] 
OATP1C1 
 
brain [53]  brain capillary endothelial 
cells [52] 
OATP2B1 brain microcapillaries 
[32]  
brain microcapillaries 
[111] 
brain capillary endothelial 
cells [49] 
    
rat    
rOATP1A4 brain [112], brain 
microcapillaries [113] 
brain [114] brain capillary endothelial 
cells: luminal and 
abluminal [114] 
rOATP1C1 brain microcapillaries 
[115] 
Brain microcapillaires 
[116] 
brain capillary endothelial 
cells: luminal and 
abluminal [52, 117] 
rOATP2B1 brain [118], brain 
microcapillaries [113] 
 brain capillary endothelial 
cells: abluminal [113] 
    
mouse    
mOATP1A1 brain microcapillaries 
[119] 
  
mOATP1A4 brain microcapillaries 
[119, 120] 
brain microcapillaries 
[87, 116, 121-125] 
brain capillary endothelial 
cells: luminal and 
abluminal [87] 
mOATP1A5 brain microcapillaries 
[119] 
 brain capillary endothelial 
cells [119] 
 
mOATP1A6 brain microcapillaries 
[119] 
  
mOATP1C1 brain microcapillaries 
[120, 126, 127] 
brain microcapillaries 
[121, 123-125] 
brain capillary endothelial 
cells [52] 
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mOATP2B1 brain microcapillaries 
[120] 
  
    
human    
OCT1 brain [128] cultured brain 
microvessel endothelial 
cells: luminal [129] 
cultured brain microvessel 
endothelial cells: luminal 
[129]  
OCT2 brain [130] cultured brain 
microvessel endothelial 
cells: luminal [129] 
cultured brain microvessel 
endothelial cells: luminal 
[129] 
OCT3 brain microcapillaries 
[32, 126] 
brain microcapillaries 
[131] 
brain capillary endothelial 
cells [131] 
OCTN2 brain microcapillaris 
[32], cultured brain 
microvessel 
endothelial cells 
[132] 
  
rat    
rOCT1 brain [133] cultured brain 
microvessel endothelial 
cells: luminal [129] 
cultured brain microvessel 
endothelial cells: luminal 
[129] 
rOCT2 brain [133] cultured brain 
microvessel endothelial 
cells: luminal [129] 
cultured brain microvessel 
endothelial cells: luminal 
[129] 
mouse    
mOCT1   cultured brain microvessel 
endothelial cells: luminal 
[129] 
mOCT2 brain [134]  cultured brain microvessel 
endothelial cells: luminal 
[129] 
mOCT3 brain microcapillaries 
[126] 
  
mOCTN2 brain microcapillaries   
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[126] 
    
rat    
rOAT2  brain microcapillaries 
[135] 
 
rOAT3 brain microcapillaries 
[136] 
brain microcapillaries 
[123, 125, 135, 137] 
brain microcapillaries: 
luminal and abluminal 
[138] 
mouse    
mOAT2 brain microcapillaries 
[126] 
  
mOAT3 brain microcapillaries 
[120, 126, 136] 
brain microcapillaries 
[121, 124, 137] 
brain microcapillaries: 
abluminal [139] 
    
rat    
rCNT2 brain microcapillaries 
[140] 
  
    
human    
ENT1  brain 
microcapillaries[32, 123, 
141] 
 
    
mouse    
mENT1  brain microcapillaries 
[123, 124] 
 
 
    
human    
MATE1 brain microcapillaries 
[131] 
brain microcapillaries 
[131] 
brain microcapillaires 
[131] 
 
Expression at the mRNA level was demonstrated by Northern blot analysis, PCR of isolated 
brain microcapillaries or by in situ hybridization. Protein expression was demonstrated by 
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Western blotting or by proteomic methods using isolated brain microcapillaries. Cellular 
localization was demonstrated by immunohistochemistry and in some instances by domain-
specific biotinylation experiments. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
35 
 
Table 2 Expression of ABC transporters at the blood brain barrier 
 
transporter mRNA expression protein expression cellular localization 
human    
ABCG2(BCRP) brain microcapillaries 
[142] 
brain microcapillaries 
[32, 123, 141] 
brain microcapillaries: 
luminal [143, 144] 
MDR1 brain microcapillaries 
[142] 
brain microcapillaries 
[32, 123] 
brain microcapillaries: 
luminal [33] 
MRP1 brain microcapillaires 
[142] 
brain microcapillaries 
[141, 145] 
brain microcapillaries: 
luminal [146] 
MRP2 brain [143]   
MRP3 brain microcapillaries 
[142] 
  
MRP4 brain microcapillaries 
[142] 
brain microcapillaries 
[32, 123, 141] 
brain microcapillaries: 
luminal [146] 
MRP5 brain [142, 143]  brain microcapillaries, 
luminal [146] 
MRP6 brain microcapillaries 
[142] 
  
    
rat    
rABCG2 brain microcapillaries 
[142, 147] 
brain microcapillaries 
[116, 137] 
brain microcapillaries: 
luminal [147] 
rMDR1A brain 
microcapillaries[113, 
142] 
brain microcapillaries 
[137] 
brain microcapillaries: 
luminal [145, 148] 
rMRP1 brain microcapillaries 
[142, 149] 
brain microcapillaries 
[116] 
brain microcapillaries: 
abluminal [113] 
rMRP2 brain microcapillaries 
[150] 
brain microcapillaries 
[151] 
brain microcapillaris: 
luminal [150] 
rMRP3 brain microcapillaries 
[152] 
brain microcapillaires 
[116] 
 
rMRP4 brain microcapillaires 
[113, 142] 
brain microcapillaries 
[116, 137] 
brain microcapillaries: 
luminal [113, 153] 
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rMRP5 brain microcapillaries 
[113, 142] 
brain microcapillaries 
[116] 
brain microcapillaries: 
abluminal [113] 
rMRP6 brain microcapillaries 
[142] 
brain microcapillaries 
[116] 
 
    
mouse    
mABCG2 brain microcapillaries 
[120, 142, 154] [155] 
brain microcapillaries 
[19, 123-125, 137] 
brain microcapillaries: 
luminal [156] 
mMDR1A brain 
microcapillaries[120, 
157] 
brain microcapillaries 
[19, 121, 124, 125] 
brain microcapillaries: 
luminal [18] 
mMRP1 brain microcapillaries 
[142] 
 brain microcaplliaries: 
abluminal [18] 
mMRP3 brain microcapillaires 
[142] 
brain microcapillaries 
[158] 
 
mMRP4 brain microcapillaries 
[120, 142] 
brain microcapillaries 
[19, 121, 123, 125] 
brain microcapillaries: 
luminal [153] 
mMRP5 brain microcapillaries 
[142] 
 brain microcapillaries: 
luminal [18] 
mMRP6 brain microcapillaries 
[142] 
  
 
Expression at the mRNA level was demonstrated by Northern blot analysis, PCR of isolated 
brain microcapillaries or by in situ hybridization. Protein expression was demonstrated by 
Western blotting or by proteomic methods using isolated brain microcapillaries. Cellular 
localization was demonstrated by immunohistochemistry and in some instances by domain-
specific biotinylation experiments. 
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Table 3 Expression of SLC transporters in choroid plexus 
 
transporter mRNA expression protein 
expression 
cellular localization 
human    
OATP1C1 
 
  choroid plexus epithelial 
cells: apical and basolateral 
[52] 
OATP3A4 
(v1 andv2) 
  choroid plexus epithelial 
cells: basolateral [159] 
    
rat    
rOATP1A1 choroid plexus [160, 
161] 
choroid plexus 
[160, 161] 
choroid plexus epithelial 
cells: apical [160] 
rOATP1A3 choroid plexus [162] choroid plexus 
[163] 
choroid plexus epithelial 
cells: apical [162] 
rOATP1A4 choroid plexus [114, 
164-167] 
 choroid plexus epithelial 
cells: basolateral [114] 
rOATP1A5 choroid plexus [161, 
165, 167] 
choroid plexus 
[161, 163] 
choroid plexus epithelial 
cells: apical [113, 161] 
rOATP1C1 choroid plexus [163, 
167, 168] 
choroid plexus 
[117] 
choroid plexus epithelial 
cells: basolateral and apical 
[52] 
rOATP2A1 choroid plexus [168, 
169] 
 crimary choroid epithelial 
cells: apical [169]l 
rOATP2B1 choroid plexus [165]  choroid plexus epithelial 
cells: apical [113] 
rOATP3A1 choroid plexus [167]   
rOATP4A1 choroid plexus [165]   
    
mouse    
mOATP1A4 choroid plexus [119] choroid plexus 
[87] 
 
mOATP1A5 choroid plexus [119] choroid plexus choroid plexus epithelial 
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[119] cells: apical[119] 
mOATP1A6 choroid plexus [119]   
mOATP1C1 choroid plexus [127, 
170] 
choroid plexus 
[171] 
choroid plexus epithelial 
cells: basolateral [171], apical 
and basolateral [52] 
    
rat    
rOCT1 choroid plexus [165]   
rOCT2 choroid plexus[168, 
172] 
  
rOCT3 choroid plexus [165, 
172] 
 choroid plexus epithelial cells 
[173] 
rOCTN1 choroid plexus [165]   
rOCTN2 choroid plexus [165, 
167] 
  
    
mouse    
mOCTN1   choroid plexus epithelial cells 
[174] 
mOCTN2   choroid plexus epithelial cells 
[174] 
mOCTN3   choroid plexus epithelial cells 
[174] 
human    
OAT1   choroid plexus epithelial cells 
[175] 
OAT3   choroid plexus epithelial 
cells[175]  
    
rat    
rOAT1 choroid plexus [95, 167, 
168] 
  
rOAT2 choroid plexus [95, 165,   
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168] 
rOAT3 choroid plexus [165, 
167] 
choroid plexus 
[176] 
choroid plexus epithelial 
cells: apical [113, 176] 
    
mouse    
mOAT1 choroid plexus [3, 95, 
177] 
  
mOAT2 choroid plexus [95]   
mOAT3 choroid plexus [3, 177]   
    
rat    
rCNT2 choroid plexus 
[165]Primary choroid 
plexus epithelial cells 
[167, 178] 
primary choroid 
plexus epithelial 
cells [178] 
 
rCNT3 choroid plexus 
[165]Primary choroid 
plexus epithelial cells 
[167, 168, 178] 
  
    
human    
ENT1  choroid plexus 
[179] 
 
ENT2  choroid plexus 
[179] 
 
ENT3  choroid plexus 
[179] 
 
    
human    
CNT3  choroid plexus 
[179] 
 
    
rat    
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rENT1 choroid plexus [165], 
choroid plexus epithelial 
cells [167, 180] 
primary choroid 
plexus epithelial 
cells [178] 
 
rENT2 choroid plexus [165, 
181]Primary choroid 
plexus epithelial cells 
[167, 178] 
primary choroid 
plexus epithelial 
cells [178] 
 
    
rPEPT1 choroid plexus [165]   
rPEPT2 choroid plexus [165, 
167, 168, 182] 
choroid plexus 
[163, 183] 
choroid plexus epithelial 
cells: apical [184], crimary 
choroid plexus epithelial 
cells: apical {Shu, 2002 
#8387 
    
mouse    
mENT1  choroid 
plexus[123, 124] 
 
 
 
Expression at the mRNA level was demonstrated by Northern blot analysis, PCR of isolated 
choroid plexus or by in situ hybridization. Protein expression was demonstrated by Western 
blotting or by proteomic methods using isolated choroid. Cellular localization was 
demonstrated by immunohistochemistry. 
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Table 4 Expression of ABC transporters in choroid plexus 
 
transporter mRNA expression protein expression cellular localization 
human    
MDR1 choroid plexus 
[185] 
choroid plexus [145, 
186] 
choroid plexus epithelial cells 
[144, 186] 
MRP1 choroid Niehof, 
2009 #8433} 
choroid plexus [145, 
186] 
choroid plexus epithelial cells 
[144, 186] 
MRP2 choroid plexus 
[185] 
  
MRP3 choroid plexus 
[185] 
  
MRP4 choroid plexus 
[185] 
 choroid plexus epithelial cells: 
basolateral [153] 
MRP5 choroid plexus 
[185] 
  
MRP6 choroid plexus 
[185] 
  
    
rat    
rABCG2 choroid plexus 
[187, 188] 
choroid plexus [188]  
rMDR1A choroid plexus 
[165, 188] 
choroid plexus [145, 
186] (C219) [188] 
choroid plexus epithelial cells 
[186] (C219)  
rMDR1B choroid plexus 
[165, 167] 
choroid plexus [145, 
186] (C219) 
choroid plexus epithelial cells 
[186] (C219) 
rMRP1 choroid plexus 
[165-167, 187, 188] 
choroid plexus [145, 
186, 189] 
choroid plexus epithelial cells: 
basolateral [18, 113, 119, 145, 
190] 
rMRP2 choroid plexus 
[165, 168, 191] 
  
rMRP3 choroid plexus 
[165] 
  
rMRP4 choroid plexus choroid plexus [163, choroid plexus epithelial cells: 
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39 
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41 
42 
43 
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47 
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[165, 167, 191] 187] basolateral [113, 153] 
rMRP5 choroid plexus 
[165, 167, 191] 
  
rMRP6 choroid plexus 
[165] 
choroid plexus [163]  
    
mouse    
mABCG2 choroid plexus [3] choroid plexus [192] choroid plexus epithelial cells: 
apical [156] 
mMDR1A choroid plexus[3]   
mMRP1 choroid plexus [3]  choroid plexus epithelial cells: 
[193], basolateral [190] 
mMRP4 choroid plexus [3, 
170] 
choroid plexus [153] choroid plexus epithelial cells: 
basolateral [52, 153] 
 
Expression at the mRNA level was demonstrated by Northern blot analysis, PCR of isolated 
choroid plexus or by in situ hybridization. Protein expression was demonstrated by Western 
blotting or by proteomic methods using isolated choroid plexus. Cellular localization was 
demonstrated by immunohistochemistry. 
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Table 5 Transporter expression in blood retinal barriers 
 
transporter mRNA expression protein expression cellular localization 
human    
OATP1A2 
 
retina [82] retina [49] retinal pigmented epithelial 
cells [82] 
OATP1B3 retina [194]   
OATP1C1 
 
  Choroid plexus epithelial 
cells: apical and basolateral 
[52] 
OATP2B1 retina [82] retina [49] retinal pigmented epithelial 
cells [82] 
    
rat    
rOATP1A4 retina [164, 195], retinal 
pigmented epithelial 
cells [196], blood retinal 
capillaries [197] 
retina [196, 198] blood retinal capillary 
endothelial cells: abluminal 
[198], retinal pigmented 
epithelial cells, apical [196, 
198, 199]  
rOATP1A5 retina [164, 196, 200] retina [196] retinal pigmented epithelial 
cells [201] 
rOATP1C1 blood retinal capillaries 
[197] 
retina [198] blood retinal capillary cells: 
luminal and abluminal [198], 
retinal pigmented epithelial 
cells, basolateral [198]  
rOATP2B1 retina [195]   
rOATP3A1 retina [195]   
rOATP4A1 retina [195, 201] retina [201]  
    
    
human    
OCT1  retinal pigmented 
epithelium [202] 
 
OCT2 retina [194]   
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OCT3 retina [194]   
OCTN2 retina [194]   
rat    
rOCT1 retina [195]{   
rOCT2 retina [195]{   
    
mouse    
mOCT3 retinal pigmented 
epithelial cells [203] 
  
mOCTN1 blood retinal capillary 
epithelial cells [204] 
  
mOCTN2 blood retinal capillary 
epithelial cells [204] 
  
    
rat    
rOAT2 retina [195]   
rOAT3 retina [195], Blood 
retinal capillaries [205] 
primary cultured 
blood retinal 
capillary 
endothelial cells 
[205] 
blood retinal capillary 
endothelial cells: abluminal 
[205] 
    
rat    
rCNT2 retina [195]   
rCNT3 retina [195]   
    
human    
PEPT1  retinal pigmented 
epithelium [202] 
 
PEPT2  retinal pigmented 
epithelium [202] 
 
    
rat    
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
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41 
42 
43 
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45 
 
rENT1 retina [195]   
rENT2 retina [195]   
    
human    
ABCG2 retina [194]   
MDR1 retina [194,] primary 
cultured retinal 
pigmented epithelial 
cells [206] 
primary cultured 
retinal pigmented 
epithelial cells 
[206] 
retinal pigmented epithelial 
cells:apical and basolateral 
[206] 
MRP1 retina [194], primary 
cultured retinal 
pigmented epithelial 
cells[207] 
primary cultured 
retinal pigmented 
epithelial cells 
[207] 
 
MRP5 retina [194]   
    
rat    
rABCG2 retina [195]   
rMDR1 blood retinal capillaries 
[197], retina [195] 
 blood retinal capillary 
endothelial cells: [208], 
luminal [205] 
retinal pigmented epithelial 
cells [208] 
rMRP1 retina [195]   
rMRP2 retina [195]   
rMRP3 retina [195]   
rMRP4 retina [195]   
rMRP5 retina [195]   
rMRP6 retina [195]   
    
mouse    
mABCG2 retina [209] retina [209] blood retinal capillary 
endothelial cells: luminal 
[209] 
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mMRP1 blood retinal capillaries 
[210] 
  
mMRP3 blood retinal capillaries 
[210] 
  
mMRP4 blood retinal capillaries 
[210] 
  
mMRP6 blood retinal capillaries 
[210] 
  
 
Expression at the mRNA level was demonstrated by PCR of isolated retinal microcapillaries. 
Protein expression was demonstrated by Western blotting using isolated retinal 
microcapillaries and cellular localization was demonstrated by immunohistochemistry. 
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